Literature DB >> 24755462

Are we ready for the 10% solution?

Helen X Chen1, Larry V Rubinstein, Lalitha K Shankar, Jeffrey S Abrams.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24755462      PMCID： PMC4012974          DOI： 10.1634/theoncologist.2014-0126

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  8 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study.

Authors:  Katherine M Krajewski; Yoko Franchetti; Mizuki Nishino; André P Fay; Nikhil Ramaiya; Annick D Van den Abbeele; Toni K Choueiri
Journal:  Oncologist       Date:  2014-04-22

3.  Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.

Authors:  R Thiam; L S Fournier; L Trinquart; J Medioni; G Chatellier; D Balvay; B Escudier; C Dromain; C A Cuenod; S Oudard
Journal:  Ann Oncol       Date:  2009-11-04       Impact factor: 32.976

4.  Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study.

Authors:  Stéphane Oudard; Rokhaya Thiam; Laure S Fournier; Jacques Medioni; Michele Lamuraglia; Florian Scotte; Elizabeth Fabre; Dennis Kim; Euloge Kpamegan; Ashok Panneerselvam; Charles A Cuenod
Journal:  Eur J Cancer       Date:  2012-02-16       Impact factor: 9.162

Review 5.  Targeted therapy for renal cell cancer: current perspectives.

Authors:  Astrid A M van der Veldt; John B Haanen; Alfons J M van den Eertwegh; Epie Boven
Journal:  Discov Med       Date:  2010-11       Impact factor: 2.970

6.  Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.

Authors:  Andrew Dennis Smith; Michael L Lieber; Shetal N Shah
Journal:  AJR Am J Roentgenol       Date:  2010-01       Impact factor: 3.959

7.  Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib.

Authors:  E Jason Abel; Stephen H Culp; Nizar M Tannir; Pheroze Tamboli; Surena F Matin; Christopher G Wood
Journal:  Eur Urol       Date:  2011-07-14       Impact factor: 20.096

8.  Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.

Authors:  Katherine M Krajewski; Mengye Guo; Annick D Van den Abbeele; Jeffrey Yap; Nikhil Ramaiya; Jyothi Jagannathan; Daniel Y C Heng; Michael B Atkins; David F McDermott; Fabio A B Schutz; Ivan Pedrosa; Toni K Choueiri
Journal:  Eur Urol       Date:  2011-02-01       Impact factor: 20.096
  8 in total
  3 in total

1.  CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?

Authors:  Yanji Luo; Jie Chen; Bingqi Shen; Meng Wang; Huasong Cai; Ling Xu; Luohai Chen; Minhu Chen; Zi-Ping Li; Shi-Ting Feng
Journal:  Eur Radiol       Date:  2018-06-06       Impact factor: 5.315

2.  Pragmatic medicine in solid cancer: a translational alternative to precision medicine.

Authors:  Jan Brábek; Daniel Rosel; Michael Fernandes
Journal:  Onco Targets Ther       Date:  2016-04-05       Impact factor: 4.147

3.  Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.

Authors:  Angela Lamarca; Jorge Barriuso; Matthew Kulke; Ivan Borbath; Heinz-Josef Lenz; Jean Luc Raoul; Neal J Meropol; Catherine Lombard-Bohas; James Posey; Sandrine Faivre; Eric Raymond; Juan W Valle
Journal:  Br J Cancer       Date:  2017-11-21       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.